Workflow
pharmaceuticals
icon
搜索文档
Stock Market Today: Dow Futures Rise After Trump Unveils New Tariffs
WSJ· 2025-09-26 08:08
President Trump says he will slap new levies on pharmaceuticals and big trucks ...
Neogen Corporation (NEOG) Slid Due to Below-Expected Revenue and Profitability
Yahoo Finance· 2025-09-24 13:06
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Initial volatility in April stemmed from increased trade policy uncertainty following President Trump's tariffs on April 2, which affected import-dependent companies. Stability returned on April 9 after a 90-day pause on new duties. Market sentiment improved in May following the White House’s suspension of reciproca ...
Cardinal Health to Announce First-Quarter Results for Fiscal Year 2026 on October 30
Prnewswire· 2025-09-23 10:45
Accessibility StatementSkip Navigation DUBLIN, Ohio, Sept. 23, 2025 /PRNewswire/ -- Cardinal Health (NYSE:Â CAH) plans to release first-quarter financial results for its fiscal year 2026 on October 30, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides an ...
FDA Grants Breakthrough Therapy Designation to Merck & Co., Inc. (MRK)’s Raludotatug Deruxtecan for Platinum-Resistant Ovarian
Yahoo Finance· 2025-09-22 21:32
Merck & Co., Inc. (NYSE:MRK) is one of the 15 Best Stocks to Invest in for Financial Stability. FDA Grants Breakthrough Therapy Designation to Merck & Co., Inc. (MRK)’s Raludotatug Deruxtecan for Platinum-Resistant Ovarian On September 15, 2025, Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo revealed that the FDA granted Breakthrough Therapy Designation to raludotatug deruxtecan for platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers expressing CDH6 after bevacizumab treatment. Th ...
Novartis ramps up US stockpiles to shield against potential tariffs
Invezz· 2025-09-20 14:41
公司战略调整 - 公司大幅增加在美国的药品库存以应对潜在关税影响 [1] - 首席执行官Vas Narasimhan主导此次战略部署 [1] 供应链管理 - 公司主动加强供应链韧性建设 [1] - 通过前置库存方式规避潜在贸易政策变动风险 [1] 区域市场布局 - 美国市场成为公司重点战略部署区域 [1] - 公司采取具体措施保障美国市场供应稳定性 [1]
Novartis has stockpiles to withstand potential Trump tariffs, CEO says
Reuters· 2025-09-20 10:00
公司战略准备 - 诺华公司已增加其在美国的药品库存 [1] - 公司已做好充分准备应对其产品可能受到特朗普总统关税影响的情况 [1]
John Bean Technologies(JBT) - 2025 Q1 - Earnings Call Presentation
2025-05-05 09:16
业绩总结 - 2025年第一季度收入为8.54亿美元,较2024年同期的3.92亿美元增长约118%[8] - 2025年第一季度调整后的EBITDA为1.12亿美元,调整后的EBITDA利润率为13.1%[8] - 2025年第一季度订单总额为9.16亿美元,较2024年同期的8.15亿美元增长约12.3%[10] - 2025年第一季度的GAAP每股收益为-3.35美元,而调整后的每股收益为0.97美元[8] - 2025年第一季度持续经营损失为173.0百万美元,而2024年同期为22.7百万美元[34] - 2025年第一季度调整后的EBITDA为112.2百万美元,2024年同期为57.4百万美元[34] - 2025年第一季度总收入为854.1百万美元,较2024年同期的392.3百万美元增长了117.0%[34] - 2025年第一季度调整后的EBITDA利润率为13.1%,低于2024年同期的14.6%[34] - 2025年第一季度自由现金流为1800万美元,过去12个月的自由现金流为216.4百万美元[36] - 2025年第一季度的经常性收入为448.9百万美元,非经常性收入为405.2百万美元[38] 未来展望 - 预计2025年第二季度收入将在8.85亿至9.15亿美元之间,调整后的EBITDA利润率为14.50%至15.25%[28] - 2025年第二季度调整后的每股收益预期为1.20至1.40美元[39] - 2025年第二季度调整后的EBITDA预期为128.0至140.0百万美元[40] - 预计2025年年底银行杠杆比率将低于3.0倍[22] 负面信息 - 由于外汇波动,JBT和Marel的收入分别受到700万美元和1000万美元的负面影响[17] - 2025年第一季度的银行总净杠杆比率为3.2倍,净债务与过去12个月调整后的EBITDA比率为3.8倍[37] - 2025年第一季度总负债约为18.9亿美元,银行杠杆比率为3.2倍[22] - 2025年第一季度总债务为1,987.5百万美元,净债务为1,886.5百万美元[37]